Overview

Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital

Status:
Not yet recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

The study to evaluate the effect of cyclosporine ( IL2 inhibitor and antiviral) verse standard care treatment on decrease ADRS, hyper inflammation, hypercytokinemia, and the mortality rate

Phase:

Phase 3

Details

Lead Sponsor:

Alexandria University

Collaborator:

Science and Technology Development Fund (STDF), ,Egypt

Treatments:

Cyclosporine
Cyclosporins
Interleukin-2